1011264-10-0

Basic information

• Product Name: 2-isobutyl-6-methoxyisonicotinic acid hydrochloride
• Synonyms: 2-isobutyl-6-methoxyisonicotinic acid hydrochloride
• CAS NO: 1011264-10-0
• Molecular Weight: 245.706
• Mol File: 1011264-10-0.mol

Chemical Properties

• CAS DataBase Reference: 2-isobutyl-6-methoxyisonicotinic acid hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-isobutyl-6-methoxyisonicotinic acid hydrochloride(1011264-10-0)
• EPA Substance Registry System: 2-isobutyl-6-methoxyisonicotinic acid hydrochloride(1011264-10-0)

Safety Data

• Hazardous Substances Data: 1011264-10-0(Hazardous Substances Data)

Upstream product

• 42521-10-8 2-chloro-6-methoxyisonicotinic acid methyl ester 
• 15855-06-8 2-chloro-6-methoxy-isonicotinic acid 
• 1011264-11-1 2-isobutyl-6-methoxy-isonicotinic acid methyl ester 

Relevant articles and documents

Novel S1P1 receptor agonists - Part 5: From amino-to alkoxy-pyridines

In a previous communication we reported on the discovery of aminopyridine 1 as a potent, selective and orally active S1P1 receptor agonist. More detailed studies revealed that this compound is phototoxic in vitro. As a result of efforts aiming at eliminating this undesired property, a series of alkoxy substituted pyridine derivatives was discovered. The photo irritancy factor (PIF) of these alkoxy pyridines was significantly lower than the one of aminopyridine 1 and most compounds were not phototoxic. Focused SAR studies showed, that 2-, 3-, and 4-pyridine derivatives delivered highly potent S1P1 receptor agonists. While the 2-pyridines were clearly more selective against S1PR3, the corresponding 3- or 4-pyridine analogues showed significantly longer oral half-lives and as a consequence longer pharmacological duration of action after oral administration. One of the best compounds, cyclopentoxy-pyridine 45b lacked phototoxicity, showed EC50 values of 0.7 and 140 nM on S1PR1 and S1PR3, respectively, and maximally reduced the blood lymphocyte count for at least 24 h after oral administration of 10 mg/kg to Wistar rats.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.

Pyridin-4-yl derivatives as immunomodulating agents

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituants are as defined in the claims.

PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS

The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.